Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation Following Functional Endoscopic Sinus Surgery
CompletedNot applicableNCT07645521
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This randomized double-blind controlled trial aims to evaluate whether bilateral trans-nasal sphenopalatine ganglion block (SPGB) using bupivacaine reduces the incidence of emergence agitation following Functional Endoscopic Sinus Surgery (FESS) compared with placebo. Secondary objectives include evaluation of postoperative pain, postoperative opioid consumption, hemodynamic parameters, postoperative nausea and vomiting, and adverse events.
Study details
- Official title
- Effect of Bilateral Trans-nasal Sphenopalatine Ganglion Block on Emergence Agitation Following Functional Endoscopic Sinus Surgery: A Double-Blind Randomized Controlled Trial
- Conditions
- Chronic Rhinosinusitis (CRS)
- Emergence Agitation
- Interventions
- Procedure: Bilateral Trans-nasal Sphenopalatine Ganglion Block
- Procedure: Sham Trans-nasal Injection
- Sponsor
- Mansoura University
- Start date
- 2025-01-05
- Primary completion
- 2026-02-07
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria * Age 18-65 years. * ASA physical status I-II. * Scheduled for elective FESS under general anesthesia. * Ability to provide informed consent. Exclusion Criteria * ASA physical status III or higher. * Known allergy or contraindication to local anesthetics. * Coagulopathy or anticoagulant therapy. * Psychiatric illness or cognitive impairment affecting agitation assessment. * Chronic opioid use or substance abuse. * Pregnancy or lactation. * Revision nasal surgery or anatomical abnormalities preventing SPGB. * Intraoperative complications requiring deviation from the study protocol.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07645521